Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: Comparing aromatase inhibitors with tamoxifen-Reference-Cited by-同舟云学术

Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: Comparing aromatase inhibitors with tamoxifen

Published:2011-02 Issue:1 Volume:20 Page:15-20
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Zhou Liheng,Yan Tingting,Jiang Yiwei,Di Genhong,Shen Zhenzhou,Shao Zhimin,Lu Jinsong

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference37 articles.

1. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases;Bardou;J Clin Oncol,2003

2. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005;Goldhirsch;Ann Oncol,2005

3. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98;Coates;J Clin Oncol,2007

4. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial;Forbes;Lancet Oncol,2008

5. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial;Dowsett;J Clin Oncol,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis;Molecular Medicine Reports;2019-12-06

2. Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting;BioMed Research International;2018-08-02

3. Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety;Cancer Prevention Research;2016-01-12

4. Evaluating the Utility of Trefoil Factor 1 as a Mammary-Specific Immunostain Compared and in Conjunction With GATA-3 and Mammaglobin in the Distinction Between Carcinoma of Breast and Lung;American Journal of Clinical Pathology;2015-09-01

5. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma;Breast Cancer Research;2014-09-30